Call for action following Health care Commission report Cancer details charity CancerBACUP is calling for action following Healthcare Commission statement, which highlights particular concerns about patient information and having less patient involvement within their care and treatment. Nearly half of most adult inpatients surveyed for the Healthcare Commission statement said they would have liked to become more involved with decisions about their care www.vardenafil-otc.com . This confirms what we know from callers to your helpline: patients remain not getting enough information throughout the NHS in order to be properly involved with decisions about their treatment, says CancerBACUP LEADER Joanne Rule. The majority of callers to your helpline are from recently diagnosed patients who want more info to help them know very well what their doctor is telling them and inform future discussions. It’s vital that the Department of Health responds to this report and takes actions to boost information provision to patients. The government’s commitment to patient choice within the NHS means little without this. Related StoriesGenetic carrier screening: an interview with Don Hardison, CEO of Great Start GeneticsRE.Function showcases future technology and improvements in deep learning softwareApplying a top restaurant model to healthcare communications: an interview with Brandi Robinson, Sanofi.
Call to speed usage of innovative advances for most breast cancer patients Breast cancer specialists and advocates at the 5th European Breast Cancer Conference called for patients to have equivalent and speedy usage of new breast cancer remedies and procedures, as as they are validated by comparative clinical trials soon. Doctors and patient organizations fear that females across Europe aren’t getting timely access to new drugs and devices that may help prolong their survival and well-being. Recent advancements in intra-operative radiation therapy and reconstructive medical procedures to the breasts have been made accessible quickly to women in the United States, but even getting on to the relevant scientific trial has proved almost impossible for his or her European counterparts. Last year Italian and English research demonstrated the feasibility of intra-operative radio – therapy. They discovered that delivering radiation directly to the open breasts during surgery appeared to be potentially as effectual as six weeks of external radiotherapy. Patients had their breast tumor surgically removed and their radiotherapy treatment all in a single stay in medical center. The new treatment also limited radiation contact with all of those other patients’ skin and other organs, preventing further tissue damage. However, there are just a few centres across European countries that can carry out intra-operative radiotherapy and several patients cannot benefit from these advances. Patients are still facing long waiting times and have to visit lengthy and tiring distances to radiotherapy centres. The mental impact of having a breast removed due to cancer has been well documented. However, new advances in reconstructive breast medical procedures can considerably improve a patient’s self-confidence and well-being; unfortunately these surgical techniques aren’t open to all European patients. Breast surgeons can now perform a mastectomy that gets rid of the malignant tumour and encircling breast tissue whilst sparing the nipple. Nipple saving medical procedures can vastly enhance the look and feel of the breast and improve a patient’s self confidence. Related StoriesStudy shows rare HER2 missense mutations do not spread breast cancer on their ownFDA grants accelerated approval for Tagrisso to take care of individuals with advanced NSCLCOvarian cancers patients with a history of oral contraceptive use have better outcomesSurgeons is now able to reconstruct a breast soon after the cancers is taken out using artificial implants or also the body’s own cells or a combined mix of cells reconstruction and implants. Breast reconstruction is a complex procedure that should be performed by a skilled plastic surgeon, unfortunately not all patients have access to surgeons who can carry out these new techniques. Another topical exemplory case of complexity in access to treatments may be the case of the medication trastuzumab . Currently the drug is licensed by the EMEA for ladies with advanced stage breasts cancer but not for those with the first stages of the disease. The recent results of four large scientific trials showed a substantial reduction in breast cancer recurrence for women with HER2 positive breast cancers, when given the medication post-surgery. Breast tumor doctors claim that the results of the four trials are sufficiently compelling to recommend adjuvant trastuzumab as a standard option after medical procedures in appropriate patients. The lagtime between the announcement of the results of the medical trials and the submission of the applications by the industry, the lack of clear definition of ‘suitable patients’, the diversity of the nationwide healthcare systems and their heterogeneous guidelines of reimbursement may prevent hundreds of patients enjoying the benefits of this drug if they need it. Dr Alberto Costa, President of the EBCC-5 conference comments, Action must be taken so that women in different countries possess equal and quick access to new and better remedies and procedures. It is regrettable that therefore many women are still not receiving the treatment that gives them the best chance of survival and best quality of life. .